US FDA spying on device staff unlawful, claim lawmakers
This article was originally published in Clinica
The US FDA may have acted unlawfully when it set up a highly-invasive electronic surveillance program to monitor employees who contacted Congress and the media with concerns about the agency’s medical device approval process, according to a joint report by two high-level lawmakers.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.